STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
10 nov. 2023 09h30 HE
|
Alvotech
CHMP positive opinion in the European Economic Area for first biosimilar to Stelara, a biologic therapy within gastroenterology, dermatology and rheumatologyPositive CHMP opinion for Uzpruvo...
Alvotech og STADA fyrst til að hljóta jákvæða afgreiðslu lyfjastofnunar Evrópu á umsókn um markaðsleyfi fyrir líftæknilyfjahliðstæðu við Stelara
10 nov. 2023 09h30 HE
|
Alvotech
Jákvæðri umsögn lyfjanefndarinnar verður vísað til framkvæmdastjórnar ESB sem tekur ákvörðun um veitingu markaðsleyfis á Evrópska efnahagssvæðinuTekjur af sölu Stelara í Evrópu nema um 380 milljörðum...
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
10 nov. 2023 09h30 HE
|
Alvotech
CHMP positive opinion in the European Economic Area for first biosimilar to Stelara, a biologic therapy within gastroenterology, dermatology and rheumatologyPositive CHMP opinion for Uzpruvo...
Alvotech tekur þátt í heilbrigðisráðstefnu Jefferies í London
07 nov. 2023 08h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) tekur þátt í heilbrigðisráðstefnu fjárfestingabankans Jefferies, sem haldin verður í London dagana 14.- 16. nóvember n.k. Stjórnendur Alvotech munu þar kynna starfsemi...
Alvotech to Present at the Jefferies 2023 London Healthcare Conference
07 nov. 2023 08h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies...
Alvotech to Present at the Jefferies 2023 London Healthcare Conference
07 nov. 2023 08h00 HE
|
Alvotech
REYKJAVIK, Iceland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
12 oct. 2023 04h00 HE
|
Alvotech
REYKJAVIK, Iceland, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech birtir nýjar upplýsingar um stöðu umsóknar um markaðsleyfi fyrir AVT04 í Bandaríkjunum
12 oct. 2023 04h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði móttekið svar frá Lyfja- og matvælaeftirliti Bandaríkjanna (FDA) við umsókn um markaðsleyfi fyrir AVT04, sem er fyrirhuguð...
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
12 oct. 2023 04h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the US Food and Drug...
Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland
05 oct. 2023 13h21 HE
|
Alvotech
Alvotech (Nasdaq: ALVO) and Íslandsbanki hf. (“Islandsbanki”) have entered into a market making agreement. According to the market making agreement, Islandsbanki places bids and offers for ALVO shares...